Achieve, Disc, and Revolution Among Recipients of First FDA National Priority Vouchers
FDA Priority Review Vouchers: Achieve Life Sciences, Disc Medicine, and Revolution Medicines are among the first recipients of the FDA's National Priority Review vouchers, aimed at expediting the review process for important medicines, reducing timelines from 10-12 months to 1-2 months.
Market Reactions: Following the announcement, Achieve Life Sciences and Disc Medicine saw significant premarket gains of approximately 25% and 20%, respectively, while Revolution Medicines increased by about 9% due to its pancreatic cancer therapy receiving a voucher.
Other Recipients: Other pharmaceutical companies, including Regeneron, Sanofi, and EMD Serono, also received priority review vouchers, with EMD Serono's fertility treatment Pergoveris highlighted by President Trump for its potential to lower costs in the market.
Program Goals: The FDA's pilot program is designed to encourage the development of drugs that address significant national priorities, such as unmet medical needs and domestic drug manufacturing.
Get Free Real-Time Notifications for Any Stock
Analyst Views on REGN
About REGN
About the author
Regeneron Pharmaceuticals Set to Announce Q4 Earnings
- Earnings Announcement: Regeneron Pharmaceuticals is set to release its Q4 2023 earnings on January 30 before market open, with consensus EPS estimate at $10.64, reflecting an 11.8% year-over-year decline, and revenue estimate at $3.78 billion, down 0.3% year-over-year.
- Historical Performance: Over the past two years, Regeneron has surpassed EPS and revenue estimates 75% of the time, indicating strong performance and stability in market expectations, which bolsters investor confidence.
- Estimate Revisions: In the last three months, EPS estimates have seen 14 upward revisions and 4 downward revisions, while revenue estimates have experienced 15 upward revisions with no downward adjustments, reflecting analysts' optimistic outlook on Regeneron's future performance.
- Industry Conference Participation: Regeneron will present at the 44th Annual J.P. Morgan Healthcare Conference, further showcasing its leadership position and strategic direction in the biopharmaceutical sector.
Stocks Recover from Significant Losses as Fed Chair Nomination Approaches
Big Tech Earnings: Investors are analyzing the earnings results from major companies like Meta Platforms, Microsoft, and Tesla, with Apple also contributing to the earnings discussions.
Government Spending Agreement: The Senate and White House have reached a spending agreement, which appears to resolve the potential for another government shutdown.
